Literature DB >> 31060977

Longitudinal Study of Visual Function in Dry Age-Related Macular Degeneration at 12 Months.

S Tammy Hsu1, Atalie C Thompson1, Sandra S Stinnett1, Ulrich F O Luhmann2, Lejla Vajzovic1, Anupama Horne1, Stefanie G Schuman1, Cynthia A Toth1, Scott W Cousins1, Eleonora M Lad3.   

Abstract

PURPOSE: To report the 1-year progression of visual impairment on psychophysical tests of visual function in patients with early and intermediate age-related macular degeneration (AMD).
DESIGN: Prospective, observational study. PARTICIPANTS: Patients with early and intermediate AMD were enrolled from the existing population at the Duke Eye Center, and healthy age-matched control participants were recruited from family members or friends of the AMD patients and from the Duke Optometry and Comprehensive Eye Clinics.
METHODS: Patients and control participants recruited during the baseline study were assessed at both 6 and 12 months after the initial study visit. Measurements of visual function included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), low-luminance deficit (LLD), microperimetry percent-reduced threshold (PRT), microperimetry average threshold (AT), and cone contrast tests (CCTs). MAIN OUTCOME MEASURES: Changes in BCVA, LLVA, LLD, microperimetry PRT, microperimetry AT, and CCT results from baseline to 6 months and to 12 months were assessed.
RESULTS: Eighty-five patients completed the 12-month examination (19 control participants, 27 early AMD patients, and 39 intermediate AMD patients). Longitudinal analysis detected significant changes from baseline within each group in microperimetry PRT and AT and in the intermediate AMD group only for BCVA and CCT results (P < 0.05).
CONCLUSIONS: Microperimetry and CCT are able to detect functional changes resulting from progression of dry AMD within a period as short as 12 months. These functional markers may be useful end points in future clinical trials that assess the effect of potential treatments for AMD.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31060977      PMCID: PMC6684849          DOI: 10.1016/j.oret.2019.03.010

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  25 in total

1.  Preservation of ganglion cell layer neurons in age-related macular degeneration.

Authors:  N E Medeiros; C A Curcio
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-03       Impact factor: 4.799

2.  No adjustments are needed for multiple comparisons.

Authors:  K J Rothman
Journal:  Epidemiology       Date:  1990-01       Impact factor: 4.822

3.  Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography.

Authors:  Sina Farsiu; Stephanie J Chiu; Rachelle V O'Connell; Francisco A Folgar; Eric Yuan; Joseph A Izatt; Cynthia A Toth
Journal:  Ophthalmology       Date:  2013-08-29       Impact factor: 12.079

4.  Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration.

Authors:  Zhichao Wu; Lauren N Ayton; Chi D Luu; Robyn H Guymer
Journal:  JAMA Ophthalmol       Date:  2015-04       Impact factor: 7.389

5.  New visual acuity charts for clinical research.

Authors:  F L Ferris; A Kassoff; G H Bresnick; I Bailey
Journal:  Am J Ophthalmol       Date:  1982-07       Impact factor: 5.258

6.  Early age-related maculopathy and self-reported visual difficulty in daily life.

Authors:  Kay Scilley; Gregory R Jackson; Artur V Cideciyan; Maureen G Maguire; Samuel G Jacobson; Cynthia Owsley
Journal:  Ophthalmology       Date:  2002-07       Impact factor: 12.079

Review 7.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

Authors:  Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong
Journal:  Lancet Glob Health       Date:  2014-01-03       Impact factor: 26.763

8.  Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography.

Authors:  Stefanie G Schuman; Anjum F Koreishi; Sina Farsiu; Sin-ho Jung; Joseph A Izatt; Cynthia A Toth
Journal:  Ophthalmology       Date:  2009-01-22       Impact factor: 12.079

9.  Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.

Authors:  Kimberly J Cocce; Sandra S Stinnett; Ulrich F O Luhmann; Lejla Vajzovic; Anupama Horne; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad
Journal:  Am J Ophthalmol       Date:  2018-03-15       Impact factor: 5.258

Review 10.  Six persistent research misconceptions.

Authors:  Kenneth J Rothman
Journal:  J Gen Intern Med       Date:  2014-01-23       Impact factor: 5.128

View more
  8 in total

1.  Immunological Aspects of Age-Related Macular Degeneration.

Authors:  Michael J Allingham; Anna Loksztejn; Scott W Cousins; Priyatham S Mettu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Machine learning OCT predictors of progression from intermediate age-related macular degeneration to geographic atrophy and vision loss.

Authors:  Eleonora Lad; Karim Sleiman; David L Banks; Sanjay Hariharan; Traci Clemons; Rolf Herrmann; Daniyar Dauletbekov; Andrea Giani; Victor Chong; Emily Y Chew; Cynthia A Toth
Journal:  Ophthalmol Sci       Date:  2022-06

3.  Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR.

Authors:  Jan H Terheyden; Frank G Holz; Steffen Schmitz-Valckenberg; Anna Lüning; Matthias Schmid; Gary S Rubin; Hannah Dunbar; Adnan Tufail; David P Crabb; Alison Binns; Clara I Sánchez; Carel Hoyng; Philippe Margaron; Nadia Zakaria; Mary Durbin; Ulrich Luhmann; Parisa Zamiri; José Cunha-Vaz; Cecília Martinho; Sergio Leal; Robert P Finger
Journal:  Trials       Date:  2020-07-18       Impact factor: 2.279

4.  Functional Correlates of Outer Retina Remodeling in Intermediate Age-Related Macular Degeneration Using Microperimetry.

Authors:  Serena Fragiotta; Eliana Costanzo; Pasquale Viggiano; Daniele De Geronimo; Gianluca Scuderi; Monica Varano; Mariacristina Parravano
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-03-02       Impact factor: 4.799

5.  Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.

Authors:  Priyatham S Mettu; Michael J Allingham; Scott W Cousins
Journal:  Ophthalmol Sci       Date:  2021-11-27

6.  Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.

Authors:  Michael J Allingham; Priyatham S Mettu; Scott W Cousins
Journal:  Ophthalmol Sci       Date:  2021-12-22

7.  Longitudinal Evaluation of Visual Function Impairments in Early and Intermediate Age-Related Macular Degeneration Patients.

Authors:  Eleonora M Lad; Vivienne Fang; Michel Tessier; Anna Rautanen; Javier Gayan; Sandra S Stinnett; Ulrich F O Luhmann
Journal:  Ophthalmol Sci       Date:  2022-05-20

Review 8.  Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.

Authors:  Yesa Yang; Hannah Dunbar
Journal:  Ophthalmologica       Date:  2021-02-10       Impact factor: 3.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.